Clinica Cayanga Medical Resources

Clinical Updates


Clinical Updates
Alzheimer's Disease
Arthritis
Benign Prostatic Hypertrophy
Chronic Lymphocytic Leukemia
Depression
Diabetes Mellitus
Dyspepsia
Erectile Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Prostate Cancer
Stroke
Tinnitus
 
Medical Library
Breaking Medical News
Clinical Tools
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
Free Medical Journal
History Taking and Physical Examination
Medical Journal (popular)
Medical Notes
Medical Organizations
Palm Tools
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator
 
 

 

7-day levofloxacin slightly better than 1-day azithromycin for pneumonia

 Clinical Question:
Is a single 2-gram dose of azithromycin more effective than levofloxacin in the treatment of mild-to-moderate community-acquired pneumonia?

Bottom Line:
A single 2.0-g dose of azithromycin microspheres was at least as effective as a 7-day course of levofloxacin in the treatment of mild to moderate community-acquired pneumonia in adult outpatients.

Reference:
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Antimicrob Agents Chemother. 2005 Oct;49(10):4035-41

Study Design:
Randomized controlled trial (double-blinded)

Setting:
Outpatient

Synopsis:
This randomized, double-blind, noninferiority study was designed to demonstrate that a single 2.0-g oral dose of a novel microsphere formulation of azithromycin was at least as effective as 7 days of levofloxacin, 500 mg/day, in the treatment of adult patients with mild to moderate community-acquired pneumonia (Fine classes I, II, and III). In total, 427 subjects were randomly assigned to receive either a single 2.0-g dose of azithromycin microspheres (n = 213) or a 7-day regimen of levofloxacin (n = 214). At baseline, 219 of 423 (51.8%) treated subjects had at least one pathogen identified by culture, PCR, or serology. The primary end point was the clinical response (cure or failure) in the "clinical per protocol" population at test of cure (days 13 to 24). Clinical cure rates were 89.7% (156 of 174) for azithromycin microspheres and 93.7% (177 of 189) for levofloxacin (treatment difference, -4.0%; 95% confidence interval, -9.7%, 1.7%). Bacteriologic success at test of cure in the "bacteriologic per protocol" population was 90.7% (97 of 107) for azithromycin microspheres and 92.3% (120 of 130) for levofloxacin (treatment difference, -1.7%; 95% confidence interval, -8.8%, 5.5%). Both treatment regimens were well tolerated; the incidence of treatment-related adverse events was 19.9% and 12.3% for azithromycin and levofloxacin, respectively. A single 2.0-g dose of azithromycin microspheres was at least as effective as a 7-day course of levofloxacin in the treatment of mild to moderate community-acquired pneumonia in adult outpatients

 

 

   

Home | Introduction | Scheduling a Visit| Laboratory Work Reaching Us | Map to our Office | About the Doctors

 

 

 ©2005 Clinica Cayanga. All rights reserved.